跳至主要内容
临床试验/JPRN-jRCTs031200124
JPRN-jRCTs031200124已完成未知

Study on the use of Convalescent plasma therapy as a COVID-19 treatment - Study on the use of Convalescent plasma therapy as a COVID-19 treatment

Saito Sho0 个研究点目标入组 11 人开始时间: 2020年9月17日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
11

研究概览

简要总结

The study was terminated; the analysis originally planned was not performed. The study was terminated in accordance with the recommendation of the Efficacy and Safety Evaluation Committee. However, this does not negate the assumption: "The rate of intubation in the existing treatment is assumed to be 25%, and this rate should be reduced by more than half (i.e., to 12% or less).

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • 1) Written consent obtained from the patient or his/her legal representative.
  • 2) COVID-19 diagnosed by PCR, LAMP, etc. and was admitted.
  • 3) Patients who satisfy the following at admission: A) SpO2 <= 94% or B) require supplimental oxygen.
  • 4) 20 years or older at enrollment

排除标准

  • 1) Pregnant or breastfeeding at enrollment
  • 2) Unable to conduct blood transfusion due to religious reasons
  • 3) Enrolled in other COVID-19 intervension study
  • 4) Previously administered with COVID-19 convalescent plasma
  • 5) Known allergy to blood products
  • 6) Deficiency of plasma protein, such as IgA
  • 7) Not appropriate to enroll determined by the PI for other reasons

研究者

发起方
Saito Sho

相似试验